References

Publication Details

1.
Keating N, Cleary P, Rossi A, et al. Use of hormone replacement therapy by postmenopausal women in the U.S. An Int Med. 1999;130:545–553. [PubMed: 10189323]
2.
Hing E, Brett KM. Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001–2003. Obstetrics & Gynecology. 2006 Jul;108(1):33–40. [PubMed: 16816053]
3.
Good WR, John VA, Ramirez M, Higgins JE. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Climacteric. 1999;2(1):29–36. [PubMed: 11915854]
4.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. Journal of the American Medical Association. 2002;288(3):321–333. [PubMed: 12117397]
5.
Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. Jama. 2003;289(20):2651–2662. [PubMed: 12771112]
6.
U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med. 2005 May 17;142(10):855–860. [PubMed: 15897536]
7.
Wells G, Tugwell P, Shea B, et al. Meta-Analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23(4):529–539. [PubMed: 12202468]
8.
MacLennan A, Lester A, Moore V. The Cochrane Library. Vol. 2. Oxford: Update Software; 2002. Oral oestrogen replacement therapy versus placebo for hot flushes (Cochrane Review).
9.
Anonymous. Undertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews CRD Report Number 4 (2nd edition). 2. York, UK: NHS Centre for Reviews and Dissemination; 2001. p. 4.
10.
Harris RP, Helfand M, Woolf SH, et al. Current methods of the third U.S. Preventive Services Task Force. Am J Prev Med. 2001;20(3S):21–35.
11.
Mulrow CD, Oxman A. How to conduct a Cochrane systematic review. Version 3.0.2.
12.
Anonymous. StatsDirect. [Accessed 2002]. http://www​.statsdirect.com/
13.
Terrin N, Schmid CH, Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol. 2005 Sep;58(9):894–901. [PubMed: 16085192]
14.
Kupperman H, Wetchler B, Blatt M. Contemporary therapy of the menopausal syndrome. JAMA. 1959;111:1627–1637. [PubMed: 14412840]
15.
Archer DR, Fischer LA, Rich D, et al. Estrace vs. Premarin for treatment of menopausal symptoms: dosage comparison study. Advances in Therapy. 1992;9(1):21–31.
16.
Utian WH, Speroff L, Ellman H, Dart C. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms. Menopause. 2005;12(6):708–715. [PubMed: 16278614]
17.
Saure A, Planellas J, Poulsen HK, Jaszczak P. A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women. Maturitas. 2000;34(2):133–142. [PubMed: 10714908]
18.
Pornel B, Spielmann D. A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17beta-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a two-year period. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2005;21(2):74–81. [PubMed: 16294458]
19.
Odmark IS, Backstrom T, Jonsson B, Bixo M. Long-term effects of two different continuous combined regimens of hormone replacement therapy on well-being. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2004;18(6):305–317. [PubMed: 15497493]
20.
Gordon SF, Thompson KA, Ruoff GE, Imig JR, Lane PJ, Schwenker CE. Efficacy and safety of a seven-day, transdermal estradiol drug-delivery system: comparison with conjugated estrogens and placebo. International Journal of Fertility & Menopausal Studies. 1995;40(3):126–134. [PubMed: 7663539]
21.
Studd JW, McCarthy K, Zamblera D, et al. Efficacy and tolerance of Menorest compared to Premarin in the treatment of postmenopausal women. Maturitas. 1995;22(2):105–114. [PubMed: 8538478]
22.
Akhila V, Pratapkumar A comparison of transdermal and oral HRT for menopausal symptom control. International journal of fertility and women’s medicine. 2006;51(2):64–69. [PubMed: 16881381]
23.
Serrano D, Mariani L, Mora S, et al. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT. Maturitas. 2006 Aug 20;55(1):69–75. [PubMed: 16500052]
24.
Al-Azzawi F, Buckler HM. Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms. Climacteric. 2003;6(2):118–127. [PubMed: 12841882]
25.
Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric : the journal of the International Menopause Society. 2005;8(1):83–92. [PubMed: 15804736]
26.
Almeida OP, Lautenschlager NT, Vasikaran S, Leedman P, Gelavis A, Flicker L. A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life. Neurobiol Aging. 2006;27(1):141–149. [PubMed: 16298249]
27.
Baksu A, Ayas B, Citak S, Kalan A, Baksu B, Goker N. Efficacy of tibolone and transdermal estrogen therapy on psychological symptoms in women following surgical menopause. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2005;91(1):58–62. [PubMed: 15970290]
28.
Crisafulli A, Marini H, Bitto A, et al. Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study. Menopause. 2004 Jul-Aug;11(4):400–404. [PubMed: 15243277]
29.
Dayal M, Sammel MD, Zhao J, Hummel AC, Vandenbourne K, Barnhart KT. Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women’s Health. 2005 Jun;14(5):391–400. [PubMed: 15989411]
30.
Diem S, Grady D, Quan J, et al. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years. Menopause (New York, NY). 2006;13(1):130–138. [PubMed: 16607109]
31.
Greenspan SL, Resnick NM, Parker RA. The effect of hormone replacement on physical performance in community-dwelling elderly women. Am J Med. 2005 Nov;118(11):1232–1239. [PubMed: 16271907]
32.
Joffe H, Hall JE, Gruber S, et al. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause (New York, NY). 2006;13(3):411–422. [PubMed: 16735938]
33.
Levine DW, Dailey ME, Rockhill B, Tipping D, Naughton MJ, Shumaker SA. Validation of the Women’s Health Initiative Insomnia Rating Scale in a multicenter controlled clinical trial. Psychosom Med. 2005;67(1):98–104. [PubMed: 15673630]
34.
Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial.[summary for patients in Ann Intern Med. 2006 Dec 19;145(12):I25; PMID: 17179054] Ann Intern Med. 2006 Dec 19;145(12):869–879. [PubMed: 17179056]
35.
Reddy SY, Warner H, Guttuso T Jr, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstetrics & Gynecology. 2006 Jul;108(1):41–48. [PubMed: 16816054]
36.
Schurmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric : the journal of the International Menopause Society. 2004;7(2):189–196. [PubMed: 15497908]
37.
Speroff L, Haney AF, Gilbert RD, Ellman H., Estradiol Acetate Investigator G. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms. Menopause (New York, NY). 2006;13(3):442–450. [PubMed: 16735941]
38.
Speroff L, Symons J, Kempfert N, Rowan J. femhrt Study I. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms. Menopause. 2000;7(6):383–390. [PubMed: 11127760]
39.
Waetjen LE, Brown JS, Vittinghoff E, et al. The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. Obstetrics & Gynecology. 2005 Nov;106(5 Pt 1):946–952. [PMC free article: PMC1557395] [PubMed: 16260511]
40.
Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C. Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomized placebo controlled pilot cross-over study. Psychoneuroendocrinology. 2005;30(4):309–315. [PubMed: 15694110]
41.
Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women. Maturitas. 2005 Feb 14;50(2):91–97. [PubMed: 15653005]
42.
Heinrich AB, Wolf OT. Investigating the effects of estradiol or estradiol/progesterone treatment on mood, depressive symptoms, menopausal symptoms and subjective sleep quality in older healthy hysterectomized women: a questionnaire study. Neuropsychobiology. 2005;52(1):17–23. [PubMed: 15942259]
43.
Wolf OT, Heinrich AB, Hanstein B, Kirschbaum C. Estradiol or estradiol/progesterone treatment in older women: no strong effects on cognition. Neurobiol Aging. 2005;26(7):1029–1033. [PubMed: 15748783]
44.
Baerug U, Winge T, Nordland G, et al. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Climacteric. 1998;1(3):219–228. [PubMed: 11907946]
45.
Bech P, Munk-Jensen N, Obel EB, Ulrich LG, Eiken P, Nielsen SP. Combined versus sequential hormonal replacement therapy: a double-blind, placebo-controlled study on quality of life-related outcome measures. Psychotherapy & Psychosomatics. 1998;67(4–5):259–265. [PubMed: 9693354]
46.
Conard J, Basdevant A, Thomas JL, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertility & Sterility. 1995;64(5):957–962. [PubMed: 7589641]
47.
Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy -- a placebo-controlled study. International Journal of Fertility & Menopausal Studies. 1995;40(2):73–78. [PubMed: 7599662]
48.
Freedman RR, Blacker CM. Estrogen raises the sweating threshold in postmenopausal women with hot flashes. Fertility & Sterility. 2002;77(3):487–490. [PubMed: 11872200]
49.
Jensen J, Christiansen C. Dose-response and withdrawal effects on climacteric symptoms after hormonal replacement therapy. A placebo-controlled therapeutic trial. Maturitas. 1983;5:125–133. [PubMed: 6415364]
50.
Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstetrics & Gynecology. 2000;95(5):726–731. [PubMed: 10775738]
51.
Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause. 2000;7(5):310–317. [PubMed: 10993030]
52.
Vikhlyaeva E, Zaidiieva Y, Lobova T, Shishkina A, Larsen S. Trisequens in perimenopausal women with climacteric syndrome: a randomized double-blind trial [abstract] Acta Obstet Gynecol Scand. 1997;58:86.
53.
Gelfand MM, Moreau M, Ayotte NJ, Hilditch JR, Wong BA, Lau CY. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: A placebo-controlled study. Menopause. 2003;10(1):29–36. [PubMed: 12544674]
54.
Yang TS, Liang WH, Chang SP, Yuan CC. Effects of period-free hormone replacement therapy in postmenopausal women in Taiwan. Chinese Medical Journal (Taipei). 2002;65(1):23–28. [PubMed: 11939671]
55.
Chung TKH, Yip SK, Lam P, Chang AMZ, Haines CJ. A randomized, double-blind, placebo-controlled, crossover study on the effect of oral oestradiol on acute menopausal symptoms. Maturitas. 1996;25:115–123. [PubMed: 8905602]
56.
Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility & Sterility. 2006 Feb;85(2):314–325. [PubMed: 16595206]
57.
Blumel JE, Roncagliolo ME, Gramegna G, Vasquez R, Estartus AT. [Double blind method of the effect of menopause symptoms, lipid profile, and endometrial thickness of continuous therapy with estradiol valerate and medroxyprogesterone acetate] Rev Chil Obstet Ginecol. 1994;59(5):354–360. [PubMed: 7569150]
58.
Jensen PB, Jensen J, Riis BJ, Rodbro P, Strom V, Christiansen C. Climacteric symptoms after oral and percutaneous hormone replacement therapy. Maturitas. 1987;9(3):207–215. [PubMed: 2963205]
59.
Marslew U, Overgaard K, Riis BJ, Christiansen C. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstetrics & Gynecology. 1992;79(2):202–210. [PubMed: 1309944]
60.
Baumgardner SB, Condrea H, Daane TA, et al. Replacement estrogen therapy for menopausal vasomotor flushes. Comparison of quinestrol and conjugated estrogens. Obstetrics & Gynecology. 1978;51(4):445–452. [PubMed: 208034]
61.
Campbell S. Double blind psychometric studies on the effects of natural estrogens on post-menopausal women. In: Campbell S, editor. The Management of the Menopause and Post Menopausal Years. Lancaster: MTP; 1976.
62.
Carranza-Lira S, Cortes-Fuentes E. Modification of vasomotor symptoms after various treatment modalities in the postmenopause. International Journal of Gynaecology & Obstetrics. 2001;73(2):169–171. [PubMed: 11336741]
63.
Coope J, Thomson JM, Poller L. Effects of “natural oestrogen” replacement therapy on menopausal symptoms and blood clotting. BMJ. 1975;4(5989):139–143. [PMC free article: PMC1674796] [PubMed: 172181]
64.
Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstetrics & Gynecology. 1998;92(6):982–988. [PubMed: 9840563]
65.
Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertility & Sterility. 2001;75(6):1065–1079. [PubMed: 11384629]
66.
Utian WH, Lederman SA, Williams BM, Vega RY, Koltun WD, Leonard TW. Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens. Obstetrics & Gynecology. 2004;103(2):245–253. [PubMed: 14754691]
67.
Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? Journal of the Royal College of General Practitioners. 1981;31(224):134–140. [PMC free article: PMC1971963] [PubMed: 6268783]
68.
Bacchi-Modena A, Bolis P, Campagnoli C, et al. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch. Maturitas. 1997;27(3):285–292. [PubMed: 9288701]
69.
De Aloysio D, Rovati LC, Giacovelli G, Setnikar I, Bottiglioni F. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. Arzneimittelforschung. 2000;50(3):293–300. [PubMed: 10758784]
70.
de Vrijer B, Snijders MP, Troostwijk AL, et al. Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women. Maturitas. 2000. pp. 47–55. [PubMed: 10687882]
71.
Notelovitz M, Cassel D, Hille D, et al. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. American Journal of Obstetrics & Gynecology. 2000;182(1 Pt 1):7–12. [PubMed: 10649149]
72.
Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB, Rowan JP. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstetrics & Gynecology. 1996;88(4 Pt 1):587–592. [PubMed: 8841224]
73.
von Holst T, Salbach B. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints. Maturitas. 2000. pp. 143–153. [PubMed: 10714909]
74.
von Holst T, Salbach B. Efficacy of a new 7-day transdermal sequential estradiol/levonorgestrel patch in women. Maturitas. 2002. pp. 231–242. [PubMed: 11886769]
75.
Utian WH, Burry KA, Archer DF, et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. American Journal of Obstetrics & Gynecology. 1999;181(1):71–79. [PubMed: 10411798]
76.
Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. American Journal of Obstetrics & Gynecology. 1993;168(3 Pt 1):824–830. [PubMed: 8456888]
77.
Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstetrics & Gynecology. 2003;102:823–834. [PubMed: 14551014]
78.
Yaffe K, Vittinghoff E, Ensrud KE, et al. Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life. Arch Neurol. 2006;63(7):945–950. [PubMed: 16831962]
79.
Women’s Health Initiative Study Group. Anderson G, Cummings S, et al. Design of the Women’s Health Initiative Clinical Trial and Observational Study. Control Clin Trials. 1998;19:61–109. [PubMed: 9492970]
80.
Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004 Apr 14;291(14):1701–1712. [PubMed: 15082697]
81.
Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women’s Health Initiative. Obstetrics & Gynecology. 2005 May;105(5 Pt 1):1063–1073. [PubMed: 15863546]
82.
Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women’s Health Initiative postmenopausal hormone trials: Overview and baseline characteristics of participants. Ann Epidemiol. 2003. pp. S78–S86. [PubMed: 14575940]
83.
Jirapinyo M, Theppisai U, Manonai J, Suchartwatnachai C, Jorgensen LN. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naive Thai women. Acta Obstetricia et Gynecologica Scandinavica. 2003;82(9):857–866. [PubMed: 12911449]
84.
Purdie DW, Empson JAC, Crichton C, MacDonald L. Hormone replacement therapy, sleep quality and psychological wellbeing. British Journal of Obstetrics & Gynaecology. 1995;102(9):735–739. [PubMed: 7547766]
85.
Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. New England Journal of Medicine. 2003;348(19):1839–1854. [PubMed: 12642637]
86.
Polo-Kantola P, Erkkola R, Helenius H, Irjala K, Polo O. When does estrogen replacement therapy improve sleep quality? American Journal of Obstetrics & Gynecology. 1998;178(5):1002–1009. [PubMed: 9609575]
87.
Soares Cn AOPJHCLS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58(6):529–534. [PubMed: 11386980]
88.
Morrison MF, Kallan MJ, Ten Have T, Katz I, Tweedy K, Battistini M. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biological Psychiatry. 2004;55(4):406–412. [PubMed: 14960294]
89.
Khoo SK, Coglan M, Battistutta D, Tippett V, Raphael B. Hormonal treatment and psychological function during the menopausal transition: an evaluation of the effects of conjugated estrogens/cyclic medroxyprogesterone acetate. Climacteric. 1998;1(1):55–62. [PubMed: 11907928]
90.
Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstetrics & Gynecology. 1991;78(6):991–995. [PubMed: 1658700]
91.
Hlatky MA, Boothroyd D, Vittinghoff E, et al. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA. 2002;287(5):591–597. [PubMed: 11829697]
92.
Ayton RA, Darling GM, Murkies AL, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. British Journal of Obstetrics & Gynaecology. 1996;103(4):351–358. [PubMed: 8605133]
93.
Bachmann G, Notelovitz M, Nachtigall L, Birgerson L. A comparative study of a low-dose estradiol vaginal ring and conjugated estrogen cream for postmenopausal urogenital atrophy. Primary Care Update for Ob/Gyns. 1997;4(3):109–115.
94.
Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause. 2000;7(3):156–161. [PubMed: 10810960]
95.
Nathorst-Boos J, Wiklund I, Mattsson LA, Sandin K, von Schoultz B. Is sexual life influenced by transdermal estrogen therapy? A double blind placebo controlled study in postmenopausal women. Acta Obstetricia et Gynecologica Scandinavica. 1993;72(8):656–660. [PubMed: 8259754]
96.
Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause. 2002;9(3):195–207. [PubMed: 11973443]
97.
Roy S, Roy S, Bonnstanfar R. Serum endocrine markers and psychosexual mood in postmenopausal women: The difference between transdermal and oral HRT (Abstract). Paper presented at: 10th World Congress on the Menopause, 2002; Berllin, Germany.
98.
Rogers R, Simon J, Ragavan V. CombiPatch significantly improves women’s sexual quality of life compared to prempro in a randomized trial (Poster). Paper presented at: American College of Obstetricians and Gynecologists 51st Annual Meeting; 2003; New Orleans, LA.
99.
Grady D, Brown J, Vittinghoff E, Applegate W, Varner E, Snyder T. Postmenopausal hormones and incontinence: The heart and estrogen/progestin replacement study. Obstetrics & Gynecology. 2001;97:116–120. [PubMed: 11152919]
100.
Suckling, Lethaby, Kennedy Local oestrogen for vaginal atrophy in postmenopausal women [Systematic Review] Cochrane Database of Systematic Reviews. 2007;1:1.
101.
Hilditch JR, Lewis J, Ross AH, et al. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women. Maturitas. 1996;24(3):177–184. [PubMed: 8844631]
102.
Buckler HA-AFUKVRMTG. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women. BJOG: an International Journal of Obstetrics & Gynaecology. 2003. pp. 753–759. [PubMed: 12892687]
103.
Gambacciani M CMCBMPBCBGGAR. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas. 2003;44(2):157–163. [PubMed: 12590012]
104.
Karlberg J, Mattsson LA, Wiklund I. A quality of life perspective on who benefits from estradiol replacement therapy. Acta Obstetricia et Gynecologica Scandinavica. 1995;74(5):367–372. [PubMed: 7778430]
105.
Skarsgard C, G EB, Ekblad S, Wiklund I, Hammar ML. Effects of estrogen therapy on well-being in postmenopausal women without vasomotor complaints. Maturitas. 2000;36(2):123–130. [PubMed: 11006499]
106.
Rebar RW, Trabal J, Mortola J. Low-dose esterified estrogens (0.3 mg/day): Long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women. Climacteric. 2000;3(3):176–182. [PubMed: 11910619]
107.
Brunner RL, Gass M, Aragaki A, et al. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women’s Health Initiative Randomized Clinical Trial. Arch Intern Med. 2005 Sep 26;165(17):1976–1986. [PubMed: 16186467]
108.
Castelo-Branco C, Martinez de Osaba MJ, Pons F, Gonzalez-Merlo J. The effect of hormone replacement therapy on postmenopausal bone loss. European Journal of Obstetrics, Gynecology, & Reproductive Biology. 1992;44(2):131–136. [PubMed: 1587378]
109.
Castelo-Branco C, Pons F, Gonzalez-Merlo J. Bone mineral density in surgically postmenopausal women receiving hormonal replacement therapy as assessed by dual photon absorptiometry. Maturitas. 1993;16(2):133–137. [PubMed: 8483425]
110.
Davas I, Altintas A, Yoldemir T, Varolan A, Yazgan A, Baksu B. Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women. Fertility & Sterility. 2003;80(3):536–540. [PubMed: 12969694]
111.
Marslew U, Riis BJ, Christiansen C. Desogestrel in hormone replacement therapy: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Eur J Clin Invest. 1991;21(6):601–607. [PubMed: 1838079]
112.
Abrahamsen B, Bendtzen K, Beck-Nielsen H. Cytokines and T-Lymphocyte subsets in healthy post-menopausal women: Estrogen retards bone loss without affecting the release of IL-1 or IL-1ra. Bone. 1997;20(3):251–258. [PubMed: 9071476]
113.
Cheng S, Sipila S, Taaffe DR, Puolakka J, Suominen H. Change in bone mass distribution induced by hormone replacement therapy and high-impact physical exercise in post-menopausal women. Bone. 2002;31(1):126–135. [PubMed: 12110425]
114.
Christiansen C, Riis BJ. 17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. Journal of Clinical Endocrinology & Metabolism. 1990;71(4):836–841. [PubMed: 2205624]
115.
Ettinger B, Genant HK, Steiger P, Madvig P. Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. American Journal of Obstetrics & Gynecology. 1992;166(2):479–488. [PubMed: 1536215]
116.
Lees B, Stevenson JC. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17[beta] and dydrogesterone. Osteoporos Int. 2001;12(4):251–258. [PubMed: 11420773]
117.
Mosekilde L, Beck-Nielsen H, Sorensen OH, et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. Maturitas. 2000;36(3):181–193. [PubMed: 11063900]
118.
Munk-Jensen N, Pors Nielsen S, Obel EB, Bonne Eriksen P. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study. British Medical Journal Clinical Research Ed. 1988;296(6630):1150–1152. [PMC free article: PMC2545620] [PubMed: 3132244]
119.
Riis BJ, Johansen J, Christiansen C. Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women. Maturitas. 1988;10(1):51–58. [PubMed: 3041248]
120.
Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA. 2003;290(8):1042–1048. [PubMed: 12941676]
121.
Arrenbrecht S, Caubel P, Garnero P, Felsenberg D. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women. Maturitas. 2004 Jul 15;48(3):197–207. [PubMed: 15207885]
122.
Greenwald MW, Gluck OS, Lang E, Rakov V. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause. 2005 Nov-Dec;12(6):741–748. [PubMed: 16278618]
123.
Liu JH, Muse KN. The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am J Obstet Gynecol. 2005;192(4):1316–1323; discussion 1323–1314. [PubMed: 15846228]
124.
Warming L, Ravn P, Nielsen T, Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. Climacteric. 2004 Mar;7(1):103–111. [PubMed: 15259289]
125.
Resch H, Pietschmann P, Krexner E, Woloszczuk W, Willvonseder R. Effects of one-year hormone replacement therapy on peripheral bone mineral content in patients with osteoporotic spine fractures. Acta Endocrinologica. 1990;123(1):14–18. [PubMed: 2389624]
126.
Gambacciani M, Spinetti A, Taponeco F, et al. Prospective evaluation of calcium and estrogen administration on bone mass and metabolism after ovariectomy. Gynecol Endocrinol. 1995;9(2):131–135. [PubMed: 7502689]
127.
Adami S, Suppi R, Bertoldo F, et al. Transdermal estradiol in the treatment of postmenopausal bone loss. Bone Miner. 1989;7(1):79–86. [PubMed: 2670019]
128.
Alexandersen P, Riis BJ, Christiansen C. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. Journal of Clinical Endocrinology & Metabolism. 1999;84(9):3013–3020. [PubMed: 10487657]
129.
Arrenbrecht S, Boermans AJ. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial. Osteoporos Int. 2002;13(2):176–183. [PubMed: 11908492]
130.
Cagnacci A, Melis GB, Soldani R, et al. Neuroendocrine and clinical effects of transdermal 17 beta-estradiol in postmenopausal women. Maturitas. 1991;13(4):283–296. [PubMed: 1775082]
131.
Cooper C, Srakkestad JA, Radowicki S, et al. Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. Osteoporos Int. 1999;9(4):358–366. [PubMed: 10550454]
132.
Filipponi P, Pedetti M, Fedeli L, et al. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. Journal of Bone & Mineral Research. 1995;10(5):697–703. [PubMed: 7639104]
133.
Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Monaco R, Gennari C. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. Journal of Bone & Mineral Research. 1997;12(4):624–631. [PubMed: 9101374]
134.
Hesley RP, Shepard KA, Jenkins DK, Riggs BL. Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline. Osteoporos Int. 1998;8(2):159–164. [PubMed: 9666940]
135.
Lufkin EG, Wahner HW, O’Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117(1):1–9. [PubMed: 1534476]
136.
McKeever C, McIlwain H, Greenwald M, et al. An estradiol matrix transdermal system for the prevention of postmenopausal bone loss. Clin Ther. 2000;22(7):845–857. [PubMed: 10945511]
137.
Perez-Jaraiz MD, Revilla M, Alvarez de los Heros JI, Villa LF, Rico H. Prophylaxis of osteoporosis with calcium, estrogens and/or eelcatonin: comparative longitudinal study of bone mass. Maturitas. 1996;23(3):327–332. [PubMed: 8794428]
138.
Notelovitz M, John VA, Good WR. Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women. Menopause. 2002;9(5):343–353. [PubMed: 12218723]
139.
Rubinacci A, Peruzzi E, Modena AB, et al. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women. Menopause. 2003;10(3):241–249. [PubMed: 12792297]
140.
Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstetrics & Gynecology. 2004 Sep;104(3):443–451. [PubMed: 15339752]
141.
Warming L, Ravn P, Christiansen C. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis. Maturitas. 2005 Feb 14;50(2):78–85. [PubMed: 15653003]
142.
Heikkinen J, Kyllonen E, Kurttila-Matero E, et al. HRT and exercise: effects on bone density, muscle strength and lipid metabolism. Maturitas. 1997;26(2):139–149. [PubMed: 9089564]
143.
Isaia G, Campagnoli C, Mussetta M, et al. Calcitonin and lumbar bone mineral content during oestrogen-progestogen administration in post-menopausal women. Maturitas. 1989;11(4):287–294. [PubMed: 2693916]
144.
Komulainen M, Tuppurainen MT, Kroger H, et al. Vitamin D and HRT: no benefit additional to that of HRT alone in prevention of bone loss in early postmenopausal women. A 2. Osteoporos Int. 1997;7(2):126–132. [PubMed: 9166392]
145.
Doren M, Reuther G, Minne HW, Schneider HP. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. American Journal of Obstetrics & Gynecology. 1995;173(5):1446–1451. [PubMed: 7503183]
146.
Agnusdei D, Civitelli R, Camporeale A, Gennari C. Calcitonin and estrogens. J Endocrinol Invest. 1990;13(8):625–630. [PubMed: 2273204]
147.
Agnusdei D, Gennari C, Bufalino L. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporos Int. 1995;5(6):462–466. [PubMed: 8695969]
148.
Aloia JF, Vaswani A, Yeh JK, Ross PL, Flaster E, Dilmanian FA. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med. 1994;120(2):97–103. [PubMed: 8256988]
149.
Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. Jama. 2003;290(13):1729–1738. [PubMed: 14519707]
150.
Civitelli R, Agnusdei D, Nardi P, Zacchei F, Avioli LV, Gennari C. Effects of one-year treatment with estrogens on bone mass, intestinal calcium absorption, and 25-hydroxyvitamin D-1 alpha-hydroxylase reserve in postmenopausal osteoporosis. Calcif Tissue Int. 1988;42(2):77–86. [PubMed: 3127028]
151.
Civitelli R, Pilgram TK, Dotson M, et al. Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial. Arch Intern Med. 2002;162(12):1409–1415. [PubMed: 12076241]
152.
Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med. 1991;90(2):171–178. [PubMed: 1847582]
153.
Gambacciani M, Ciaponi M, Cappagli B, Piaggesi L, Genazzani AR. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women. Maturitas. 1997;28(1):75–81. [PubMed: 9391998]
154.
Genant HK, Cann CE, Ettinger B, Gordan GS. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med. 1982;97(5):699–705. [PubMed: 6291439]
155.
Greenspan S, Bankhurst A, Bell N. Effects of alendronate and estrogen alone and in combination on bone mass and turnover in postmenopausal osteoporosis [abstract] Journal of Bone & Mineral Research. 1998;S174:1107.
156.
Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med. 1998;338(8):485–492. [PubMed: 9443925]
157.
Leung KY, Lee TK, Lee CN, Sum TK, Chan MYM, Tong CM. The effects of different dosages of oestrogen on the bone mineral density of postmenopausal Hong Kong Chinese women: Randomised controlled trial. Hong Kong Medical Journal. 1999;5(1):9–14. [PubMed: 11821561]
158.
Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstetrics & Gynecology. 1984;63(6):759–763. [PubMed: 6374537]
159.
Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstetrics & Gynecology. 1990;76(2):290–295. [PubMed: 2371033]
160.
Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287(20):2668–2676. [PubMed: 12020302]
161.
Meschia M, Brincat M, Barbacini P, Crossignani PG, Albisetti W. A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int. 1993;53(1):17–20. [PubMed: 8394192]
162.
Mizunuma H, Okano H, Soda M, et al. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study. Maturitas. 1997;27(1):69–76. [PubMed: 9158080]
163.
Anonymous. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA. 1996;276(17):1389–1396. [PubMed: 8892713]
164.
Recker RR, Saville PD, Heaney RP. Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med. 1977;87(6):649–655. [PubMed: 201203]
165.
Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. Ann Intern Med. 1999;130(11):897–904. [PubMed: 10375338]
166.
Rosen CJ, Chesnut CH 3rd, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. Journal of Clinical Endocrinology & Metabolism. 1997;82(6):1904–1910. [PubMed: 9177404]
167.
Villareal DT, Binder EF, Williams DB, Schechtman KB, Yarasheski KE, Kohrt WM. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. JAMA. 2001;286(7):815–820. [PubMed: 11497535]
168.
Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med. 1998;104(3):219–226. [PubMed: 9552083]
169.
Gambacciani M, Ciaponi M, Cappagli B, et al. Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy. Maturitas. 2003;45(3):175–183. [PubMed: 12818462]
170.
Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. Jama. 2003;289(19):2525–2533. [PubMed: 12759324]
171.
Reid IR, Eastell R, Fogelman I, et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med. 2004 Apr 26;164(8):871–879. [PubMed: 15111373]
172.
Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int. 2005 Apr;16(4):372–379. [PubMed: 15654581]
173.
Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women’s health initiative randomized trial. Journal of Bone & Mineral Research. 2006 Jun;21(6):817–828. [PubMed: 16753012]
174.
Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med. 1997;157(22):2609–2615. [PubMed: 9531230]
175.
Greendale GA, Espeland M, Slone S, Marcus R, Barrett-Connor E. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Archives of Internal Medicine. 2002;162(6):665–672. [PubMed: 11911720]
176.
Neele SJM, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone. 2002;30(4):599–603. [PubMed: 11934652]
177.
Cheng GJ, Liu JL, Zhang Q, et al. Nylestriol replacement therapy in postmenopausal women. Chin Med J. 1993;106(12):911–916.
178.
Christiansen C, Christensen MS, Rodbro P, Hagen C, Transbol I. Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Eur J Clin Invest. 1981;11(4):305–309. [PubMed: 6795047]
179.
Christiansen C, Mazess RB, Transbol I, Jensen GF. Factors in response to treatment of early postmenopausal bone loss. Calcif Tissue Int. 1981;33(6):575–581. [PubMed: 6275967]
180.
Christensen MS, Hagen C, Christiansen C, Transbol I. Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions. American Journal of Obstetrics & Gynecology. 1982;144(8):873–879. [PubMed: 6756151]
181.
Finn Jensen G, Christiansen C, Transbol I. Treatment of post menopausal osteoporosis. A controlled therapeutic trial comparing oestrogen/gestagen, 1,25-dihydroxy-vitamin D3 and calcium. Clin Endocrinol. 1982;16(5):515–524. [PubMed: 7044620]
182.
Harris ST, Genant HK, Baylink DJ, et al. The effects of estrone (Ogen) on spinal bone density of postmenopausal women. Arch Intern. Med. 1991;151(10):1980–1984. [PubMed: 1929686]
183.
Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA. 1996;276(17):1397–1403. [PubMed: 8892714]
184.
MacIntyre I, Stevenson JC, Whitehead MI, Wimalawansa SJ, Banks LM, Healy MJ. Calcitonin for prevention of postmenopausal bone loss. Lancet. 1988;1(8591):900–902. [PubMed: 2895829]
185.
Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. N Engl J Med. 1987;316(4):173–177. [PubMed: 3540668]
186.
Riis BJ, Nilas L, Christiansen C. Does calcium potentiate the effect of estrogen therapy on postmenopausal bone loss? Bone Miner. 1987;2(1):1–9. [PubMed: 3504720]
187.
Horsman A, Gallagher JC, Simpson M, Nordin BE. Prospective trial of oestrogen and calcium in postmenopausal women. BMJ. 1977;2(6090):789–792. [PMC free article: PMC1631969] [PubMed: 912324]
188.
Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med. 1995;99(1):36–42. [PubMed: 7598140]
189.
Palacios S, Menendez C, Jurado AR, Vargas JC. Effects of percutaneous oestradiol versus oral oestrogens on bone density. Maturitas. 1995;20(2–3):209–213. [PubMed: 7715474]
190.
Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet. 1976;1(7968):1038–1041. [PubMed: 57448]
191.
Lindsay R, Hart DM, Purdie D, Ferguson MM, Clark AS, Kraszewski A. Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clinical Science & Molecular Medicine. 1978;54(2):193–195. [PubMed: 340117]
192.
Doren M, Nilsson JA, Johnell O. Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: A meta-analysis. Hum Reprod. 2003;18(8):1737–1746. [PubMed: 12871893]
193.
Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605–613. [PubMed: 9718051]
194.
Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):58–66. [PubMed: 12090863]
195.
Goldstein SR, Johnson S, Watts NB, Ciaccia AV, Elmerick D, Muram D. Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen. Menopause. 2005 Mar;12(2):160–164. [PubMed: 15772563]
196.
Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstetrics & Gynecology. 2005 Apr;105(4):779–787. [PubMed: 15802405]
197.
Kristensen SR, Abrahamsen B, Madsen JS, et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thromb Haemost. 2006 May;95(5):915–916. [PubMed: 16676096]
198.
Langer RD, Landgren BM, Rymer J, Helmond FA, Investigators O. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. American Journal of Obstetrics & Gynecology. 2006 Nov;195(5):1320–1327. [PubMed: 16875644]
199.
Utian WH, Gass MLS, Pickar JH. Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women. Menopause. 2004 May-Jun;11(3):306–314. [PubMed: 15167310]
200.
Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA. 2002;288:49–57. [PubMed: 12090862]
201.
Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan J. Postmenopausal hormone replacement therapy: Scientific review. JAMA. 2002. in press. [PubMed: 12186605]
202.
Miller J, Chan BKS, Nelson HD. Hormone replacement therapy and risk of venous thromboembolism: System evidence review. Ann Intern Med. 2002. in press.
203.
De Lignie, De Vathaire B, Fournier FS, et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric. 2002. pp. 332–340. [PubMed: 12626212]
204.
Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women’s Health Initiative Memory Study. JAMA. 2004 Jun 23;291(24):2959–2968. [PubMed: 15213207]
205.
Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA : the journal of the American Medical Association. 2003;289(20):2663–2672. [PubMed: 12771113]
206.
Resnick SM, Coker LH, Maki PM, Rapp SR, Espeland MA, Shumaker SA. The Women’s Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline. Clin. 2004;1(5):440–450. [PubMed: 16279282]
207.
Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA. 2004 Jun 23;291(24):2947–2958. [PubMed: 15213206]
208.
Shumaker SA, Reboussin BA, Espeland MA, et al. The Women’s Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials. 1998 Dec;19(6):604–621. [PubMed: 9875839]
209.
Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol. 1994;83:5–11. [PubMed: 8272307]
210.
Grady D, Gebretsadik T, Ernster VL, Petitti DB. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstetrics & Gynecology. 1995;85:304–313. [PubMed: 7824251]
211.
Lacey JJ, Mink P, Lubin J, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 2002;288:334–341. [PubMed: 12117398]
212.
Rodriquez C, Patel A, Calle E, et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of U.S. women. JAMA. 2001;285:1460–1465. [PubMed: 11255422]
213.
Persson I, Yuen J, Bergkvist L, et al. Cancer incidence and mortality tin women receiving estrogen and estrogen-progestin replacement therapy - long term followup of a Swedish cohort. Int J Cancer. 1996;67:327–332. [PubMed: 8707404]
214.
Farquhar CM, Marjoribanks, et al. Long term hormone therapy for perimenopausal and postmenopausal women [Systematic Review] Cochrane Database of Systematic Reviews. 2007;1:1. [PubMed: 22786488]